Correlation Between Intellia Therapeutics and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Intellia Therapeutics and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Intellia Therapeutics and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Intellia Therapeutics and Crispr Therapeutics AG, you can compare the effects of market volatilities on Intellia Therapeutics and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Intellia Therapeutics with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Intellia Therapeutics and Crispr Therapeutics.
Diversification Opportunities for Intellia Therapeutics and Crispr Therapeutics
0.94 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between Intellia and Crispr is 0.94. Overlapping area represents the amount of risk that can be diversified away by holding Intellia Therapeutics and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Intellia Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Intellia Therapeutics are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Intellia Therapeutics i.e., Intellia Therapeutics and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Intellia Therapeutics and Crispr Therapeutics
Given the investment horizon of 90 days Intellia Therapeutics is expected to generate 0.94 times more return on investment than Crispr Therapeutics. However, Intellia Therapeutics is 1.06 times less risky than Crispr Therapeutics. It trades about 0.28 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.19 per unit of risk. If you would invest 938.00 in Intellia Therapeutics on April 30, 2025 and sell it today you would earn a total of 312.00 from holding Intellia Therapeutics or generate 33.26% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Intellia Therapeutics vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Intellia Therapeutics |
| Crispr Therapeutics |
Intellia Therapeutics and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Intellia Therapeutics and Crispr Therapeutics
The main advantage of trading using opposite Intellia Therapeutics and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Intellia Therapeutics position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.| Intellia Therapeutics vs. Editas Medicine | Intellia Therapeutics vs. Caribou Biosciences | Intellia Therapeutics vs. Crispr Therapeutics AG | Intellia Therapeutics vs. Verve Therapeutics |
| Crispr Therapeutics vs. Intellia Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Vertex Pharmaceuticals | Crispr Therapeutics vs. Beam Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Complementary Tools
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |